DK2327407T3 - Profylaktisk og/eller terapeutisk middel til funktionelle gastrointestinale sygdomme - Google Patents

Profylaktisk og/eller terapeutisk middel til funktionelle gastrointestinale sygdomme

Info

Publication number
DK2327407T3
DK2327407T3 DK09816166.4T DK09816166T DK2327407T3 DK 2327407 T3 DK2327407 T3 DK 2327407T3 DK 09816166 T DK09816166 T DK 09816166T DK 2327407 T3 DK2327407 T3 DK 2327407T3
Authority
DK
Denmark
Prior art keywords
prophylactic
therapeutic agent
gastrointestinal diseases
functional gastrointestinal
functional
Prior art date
Application number
DK09816166.4T
Other languages
English (en)
Inventor
Satoru Tamaoki
Jun Sato
Katsuichi Sudo
Original Assignee
Aska Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharm Co Ltd filed Critical Aska Pharm Co Ltd
Application granted granted Critical
Publication of DK2327407T3 publication Critical patent/DK2327407T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
DK09816166.4T 2008-09-26 2009-09-24 Profylaktisk og/eller terapeutisk middel til funktionelle gastrointestinale sygdomme DK2327407T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008248932 2008-09-26
PCT/JP2009/066533 WO2010035751A1 (ja) 2008-09-26 2009-09-24 機能性消化管障害の予防及び/又は治療剤

Publications (1)

Publication Number Publication Date
DK2327407T3 true DK2327407T3 (da) 2014-08-25

Family

ID=42059749

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09816166.4T DK2327407T3 (da) 2008-09-26 2009-09-24 Profylaktisk og/eller terapeutisk middel til funktionelle gastrointestinale sygdomme

Country Status (14)

Country Link
US (1) US8980872B2 (da)
EP (1) EP2327407B1 (da)
JP (1) JP5567484B2 (da)
KR (1) KR20110071096A (da)
CN (1) CN102164599B (da)
AU (1) AU2009297562B2 (da)
BR (1) BRPI0918997A2 (da)
CA (1) CA2736285C (da)
DK (1) DK2327407T3 (da)
ES (1) ES2496190T3 (da)
PL (1) PL2327407T3 (da)
PT (1) PT2327407E (da)
RU (1) RU2011116400A (da)
WO (1) WO2010035751A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
PL2493471T3 (pl) 2009-10-26 2020-10-19 Borody Nowa skojarzona terapia jelitowa
US20190298783A1 (en) 2018-03-28 2019-10-03 Morinaga Milk Industry Co., Ltd. Composition for relieving stress, pharmaceutical composition and food and drink composition and method for relieving stress using the composition for relieving stress

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
JPS6123192A (ja) 1984-07-11 1986-01-31 三菱電機株式会社 マトリクス型表示装置の製造方法
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
US20090233888A1 (en) * 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
CN103263668A (zh) 2006-03-09 2013-08-28 萨利克斯药品公司 利福昔明抗直肠功能障碍制剂
HUE025306T2 (hu) * 2006-08-02 2016-01-28 Salix Pharmaceuticals Inc Sugárterápia által okozott bélgyulladás kezelésére irányuló módszer

Also Published As

Publication number Publication date
EP2327407A4 (en) 2012-02-29
ES2496190T3 (es) 2014-09-18
BRPI0918997A2 (pt) 2015-12-01
JP5567484B2 (ja) 2014-08-06
EP2327407A1 (en) 2011-06-01
WO2010035751A1 (ja) 2010-04-01
RU2011116400A (ru) 2012-11-10
CA2736285C (en) 2016-08-23
JPWO2010035751A1 (ja) 2012-02-23
US8980872B2 (en) 2015-03-17
CA2736285A1 (en) 2010-04-01
US20110152517A1 (en) 2011-06-23
AU2009297562B2 (en) 2015-04-23
CN102164599B (zh) 2014-07-23
KR20110071096A (ko) 2011-06-28
CN102164599A (zh) 2011-08-24
AU2009297562A1 (en) 2010-04-01
PT2327407E (pt) 2014-09-10
EP2327407B1 (en) 2014-07-09
PL2327407T3 (pl) 2014-12-31

Similar Documents

Publication Publication Date Title
NO2017002I2 (no) Kobicistat eller farmasøytisk akseptabelt salt derav og atazanavir eller farmasøytisk akseptabelt salt derav
DK2437762T3 (da) Kunstige tårer og terapeutiske anvendelser
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK3351558T3 (da) Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
DK3067064T3 (da) Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
DK2304568T3 (da) Fremgangsmåde og system til fordelt raid-implementering
DK2470191T3 (da) Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande
DK2405869T3 (da) Fedmebehandling
DK2479174T3 (da) 6-aminoquinazolin- eller 3-cyanquinolinderivater, fremstillingsfremgangsmåder og farmaceutiske anvendelser deraf
DK3092901T3 (da) Quinolonanaloger og fremgangsmåder relateret dertil
DK3560915T3 (da) Polypeptider med oxidoreduktaseaktivitet og anvendelser deraf
DK2273975T3 (da) Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
DK2192933T3 (da) Materialer til oftalmologisk og ortorhinolaryngologisk anordning
DK2337837T3 (da) Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf
DK2288643T3 (da) Skumpolyestere og fremgangsmåder til fremstilling heraf
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2160336T3 (da) Forbindelsesmekanisme og fremgangsmåde
BRPI0919759A2 (pt) polipeptídeos para tratamento e prevenção de adesões
DK3216457T3 (da) Forbindelser og fremgangsmåder til forebyggelsen eller behandlingen af restenose
NO20084074L (no) Fremgangsmåte og system for behandling av gass
DK2294491T3 (da) Reaktionsenhed og strømningssplitter
DK2274619T3 (da) Slimhindereceptor og anvendelser deraf
DK2276760T3 (da) Kondenserede ringforbindelser og anvendelse deraf
DK1999403T3 (da) Multikoblingssystem og fremgangsmåde relateret dertil
DK2131682T3 (da) Autoklave og fremgangsmåde